Search Results
Your search for all items matches 34730 pages
Showing 24251 - 24300Spectrin Gene Identified as a Biomarker in HPV-Negative Oral Cavity Squamous Cell Carcinoma
Researchers have identified a gene that may help to predict survival outcomes in patients with cancer of the mouth and tongue. Patients whose tumors express a gene called spectrin are 4.6 times more likely to die at any given time, according to a study by researchers at Loyola Medicine and Loyola...
Potential Targets for Loss of Appetite/Cachexia Related to Interleukin 18 Activity Identified in Early Studies
Loss of appetite during illness is a common and potentially debilitating phenomenon. In cancer patients especially, it can even shorten lifespan. Scientists at The Scripps Research Institute (TSRI) have discovered how an immune system molecule controls a brain circuit and reduces appetite. Their...
Assessing the Accuracy and Readability of Online Health Information for Patients With Pancreatic Cancer
Online information on pancreatic cancer overestimates the reading ability of the overall population and lacks accurate information about alternative therapy, according to a study published by Storino et al in JAMA Surgery. The degree to which patients are empowered by written educational materials ...
Trastuzumab/Lapatinib Active in Refractory, KRAS Codon 12/13 Wild-Type, HER2-Positive Metastatic Colorectal Cancer
Dual HER2 inhibition with trastuzumab (Herceptin) and lapatinib (Tykerb) was active in patients with refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer, according to an Italian phase II trial reported by Sartore-Bianchi et al in The Lancet Oncology. Study Details...
Pembrolizumab Active in Virus-Positive and ‑Negative Advanced Merkel Cell Carcinoma
The PD-1 (programmed cell death protein 1) inhibitor pembrolizumab (Keytruda) was active in advanced Merkel cell carcinoma in both Merkel cell polyomavirus (MCP)-positive and -negative tumors, according to Nghiem et al, who reported their phase II study findings in The New England Journal of...
FDA Grants Priority Review for BLA for Olaratumab in Advanced Soft-Tissue Sarcoma
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the biologics license application (BLA) for olaratumab, a platelet-derived growth factor receptor alpha (PDGFRα) antagonist, in combination with doxorubicin, for the...
FDA Grants sBLA for Blinatumomab in Pediatric Patients With Ph–Negative Relapsed/Refractory B-Cell Precursor ALL
Amgen announced on May 3 that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include new data supporting the treatment of pediatric and adolescent patients with Philadelphia...
Similar Outcomes Reported With ABVD vs BEACOPP in High-Risk Advanced Hodgkin Lymphoma
In a phase III trial (EORTC 20012 Intergroup Trial) reported by Carde et al in the Journal of Clinical Oncology, similar outcomes were achieved with eight cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) vs four cycles each of escalated BEACOPP (bleomycin, etoposide, doxorubicin,...
Effects of High Residential Segregation and Neighborhood Characteristics on Early-Stage NSCLC Surgery
Black residents of highly segregated neighborhoods were less likely to receive surgery for early-stage non–small cell lung cancer (NSCLC) than their peers in less-segregated neighborhoods, according to a study published by Johnson et al in Cancer Epidemiology, Biomarkers & Prevention....
ESTRO 2016: New Study Sheds Light on Mastectomy vs Breast-Conserving Therapy in Older vs Younger Patients With Early Breast Cancer
New research presented at the ESTRO 35 Conference on April 30 (Abstract OC-0052) has shown women aged younger than 45 years with early-stage breast cancer that had not spread to the lymph nodes and who opted for breast-conserving therapy with radiation therapy had a 13% higher risk of developing a...
ESTRO 2016: Radiotherapy vs Chemotherapy in a Study of Patients With Early Stage II Testicular Cancer
A large study of testicular cancer patients showed that radiation therapy was more effective than chemotherapy for patients with stage IIa disease (where one or more regional lymph nodes contain cancer cells, but they are less than 2 cm in diameter). These findings, presented at the ESTRO 35...
Study Finds Cancer Mortality Risks From Long-Term Exposure to Ambient Fine Particulate Matter
Long-term exposure to ambient fine particulate matter, a mixture of environmental pollutants, was associated with increased risk of mortality for many types of cancer in an elderly Hong Kong population, according to a study published by Wong et al in Cancer Epidemiology, Biomarkers &...
Tight Junction Protein 1 May Identify Sensitivity to Proteasome Inhibitors in Patients With Multiple Myeloma
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by researchers from The...
ESTRO 2016: SBRT in Early-Stage Lung Cancer Linked to Increased Risk of Noncancer Deaths
Researchers have found that treating patients who have early-stage non–small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer, according to findings presented at the European Society...
ESTRO 2016: Radiation and L19-IL2 Immunotherapy Combination Shows Activity in Preclinical Models
Radiation therapy not only targets and destroys cancer cells, but also helps to activate the immune system against their future proliferation. However, this immune response is often not strong enough to be able to completely eradicate tumors, and even when it is, its effect is limited to the area...
ESTRO 2016: Failure to Publish Phase III Radiotherapy Trial Results Exposes Patients to Risks Without Providing Benefits for Others
Although the publication of results of clinical trials carried out in the United States within 12 months of their completion has been mandatory since 2007, a remarkably high number of phase III radiotherapy trials did not do so, according to new research presented at the European Society for...
Genomic Profiling of Orbital and Ocular Adnexal Lymphomas
In a study reported in Modern Pathology, Cani et al used next-generation sequencing to identify actionable mutations in orbital and ocular adnexal lymphomas, finding frequent alterations in MYD88 and chromatin modifiers. Study Details The study involved next-generation sequencing of 36...
Study Links Residential Radon Exposure to Increased Risk of Hematologic Malignancies in Women
A new report published by Teras et al in Environmental Researchfound a statistically significant, positive association between high levels of residential radon and the risk of hematologic cancer (lymphoma, myeloma, and leukemia) in women. The study is the first prospective, population-based study...
Study Finds No Association Between Anthracycline-Based Chemotherapy and Cognitive Decline in Women With Breast Cancer
A new study by University of California, Los Angeles (UCLA) researchers published by Van Dyk et al in JAMA Oncology found that commonly used chemotherapy drugs showed no association with cognitive decline following treatment in women with breast cancer. The report addresses recent concerns that the ...
Cancer Screening Using Digital Mammography Alone or With Tomosynthesis in Varying Breast Densities
In a study published by Rafferty et al in JAMA, Elizabeth A. Rafferty, MD, formerly of Massachusetts General Hospital, and colleagues evaluated the screening performance of digital mammography combined with tomosynthesis compared with digital mammography alone for women with varying levels of...
Validation of Rapid Plasma Genotyping for Detecting EGFR and KRAS Mutations in Advanced Lung Cancer
As reported in JAMA Oncology, Sacher et al have prospectively validated a plasma droplet digital polymerase chain reaction (ddPCR) assay for detecting common EGFR and KRAS mutations in patients with advanced nonsquamous non–small cell lung cancer. Study Details The study involved 180...
Poor Understandability of Dense Breast Notifications Sent to Women Following Screening Mammography
In a study published by Kressin et al in JAMA, Nancy R. Kressin, PhD, of the Veterans Affairs Boston Healthcare System, Boston University School of Medicine, and colleagues examined the content, readability, and understandability of dense breast notifications sent to women following screening...
New Study Suggests Cholesterol Levels, Not Statins, Influence Colorectal Cancer Risk
Long-term use of the cholesterol-lowering drugs statins does not appear to decrease a patient’s risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine published by Mamtani et al in PLOS Medicine. The observational analysis of over 100,000 patients’...
A Critical Analysis of Early Bladder Cancer Recurrence After Laparoscopic Radical Cystectomy
Although laparoscopic radical cystectomy and robotic-assisted radical cystectomy continue to grow in popularity and are successful in the treatment of bladder cancer, they are still considered experimental approaches. Using data collected by the Section of Uro-Technology of the European Association ...
Canadian Study Suggests Increased Risk of Cardiac Dysfunction With Trastuzumab-Based Regimens for Breast Cancer
In a Canadian retrospective population-based cohort study reported in the Journal of Clinical Oncology, Thavendiranathan et al found that trastuzumab (Herceptin)-based regimens were associated with an increased risk of treatment-related cardiac dysfunction among women with breast cancer, with an...
ASCO Adapts CCO Guideline on Selection of Optimal Adjuvant Therapy for Breast Cancer
ASCO has adapted a Clinical Care Ontario (CCO) clinical practice guideline on the selection of optimal adjuvant chemotherapy for early breast cancer and adjuvant targeted therapy for HER2-positive breast cancer, as reported in the Journal of Clinical Oncology. The adaptation was based on review by...
Donor Epstein-Barr Virus Status Affects Risk for Graft-vs-Host Disease but Not Survival in Acute Leukemia After HSCT
Positive donor Epstein-Barr virus (EBV) serostatus increases the risk for graft-vs-host disease but does not affect relapse-free or overall survival among patients with acute leukemia receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT), according to a study from the Acute...
Addition of Everolimus to Trastuzumab and Chemotherapy May Benefit Some Patients With Advanced HER2-Positive Breast Cancer
In an analysis of the phase III BOLERO trials reported in the Journal of Clinical Oncology, André et al found that the addition of everolimus (Afinitor) to trastuzumab (Herceptin) and chemotherapy was associated with a progression-free survival benefit in advanced HER2-positive breast cancer ...
Solid Organ Transplant Recipients With Preexisting Malignancies in Remission May Be More Likely to Die, Develop New Cancers
Patients who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer, or develop a new cancer than organ recipients who did not previously have cancer, a new study published by Acuna et al in the journal Transplantation has found. However, the increased...
Stereotactic Body Radiation Therapy May Offer a Higher Cure Rate in Prostate Cancer Than More Traditional Approaches
A 5-year study published by Hannan et al in the European Journal of Cancer showed that stereotactic body radiation therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons...
FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy
On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The...
FDA Grants Breakthrough Designation to Nivolumab in Squamous Cell Carcinoma of the Head and Neck
On April 25, 2016, the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to the anti–programmed death 1 antibody nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck that previously received...
AACR 2016: Neoadjuvant Trastuzumab Emtansine Plus Pertuzumab May Improve Outcomes for Women With HER2-Positive Breast Cancer
Results from the I-SPY 2 TRIAL show that a neoadjuvant therapy combination of the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) and pertuzumab (Perjeta) was more beneficial than paclitaxel plus trastuzumab for women with HER2-positive invasive breast cancer, according to research...
Study Finds Radiosensitivity Differences Between Liver Metastases Based on Primary Histology
Radiation is a commonly used therapeutic option to treat liver metastases, with the majority of tumors maintained under control after a year. However, some patients do not respond as well to radiation treatment, and the factors that predict patient outcomes are unclear. Moffitt Cancer Center...
Amplification of 9p24.1 Associated With Advanced Stage and Poorer Outcome in Classic Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Roemer et al identified PD-L1 (programmed cell death ligand 1) and PD-L2 genetic alterations in patients with classic Hodgkin lymphoma, finding that 9p24.1 amplification was common and associated with advanced-stage disease and poorer...
Advantage of Afatinib vs Gefitinib in First-Line Treatment of EGFR-Mutant NSCLC
The irreversible ErbB family inhibitor afatinib (Gilotrif) was associated with improvement in progression-free survival and time to treatment failure vs the reversible EGFR (epidermal growth factor receptor) inhibitor gefitinib (Iressa) in the first-line treatment of EGFR-mutant non–small...
Natural Cancer Remedies
The cost and side effects associated with traditional cancer therapy are major concerns, and in part many patients are seeking natural remedies such as graviola, curcumin, and moringa, due to these concerns. Traditional cancer therapy is increasingly effective, and oncologists are achieving better...
Blue Ribbon Panel to Help Guide Cancer Moonshot Initiative
As described in the full report on page 39, the National Cancer Institute (NCI) announced a Blue Ribbon Panel of experts and advocates who will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National Cancer Moonshot Initiative. Members of the research community and...
Severe Adverse Event Clusters Identified Using NCI Common Terminology Criteria
Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), researchers from Columbia University, New York, and Fred Hutchinson Cancer Research Center, Seattle, identified six severe adverse event clusters in patients with advanced prostate cancer. The clusters...
Earlier Hospice Enrollment, Avoiding ICU Admissions, and Not Dying in the Hospital Associated With Perceptions of Better End-of-Life Care
Three measures of aggressive end-of-life care “were associated with relatively large differences in family member–reported quality ratings for end-of-life care and a lower likelihood that patients with advanced-stage cancer received care congruent with their preferences,” according to a study in...
High-Accuracy Metabolomic Detection of Early-Stage Ovarian Cancer
As reported in Scientific Reports, Gaul and colleagues used high-performance mass spectrometry to interrogate the serum metabolome of patients with early-stage ovarian cancer and healthy controls. They were able to define a linear support vector machine model of 16 metabolites that identified...
Choline Kinase Alpha as Androgen Receptor Chaperone and Prostate Cancer Target
As reported in the Journal of the National Cancer Institute, Asim and colleagues found that choline kinase alpha (CHKA) acts as a chaperone for the androgen receptor (AR) and may serve as a therapeutic target in prostate cancer. CHKA expression was found to be androgen regulated in cell lines,...
Potential Role for HSP70 Peptide Aptamer in Restoring Anticancer Immune Response
Exosomes can activate myeloid-derived suppressor cells via interaction of membrane heat shock protein 70 (HSP70) with Toll-like receptor 2 (TLR2) on the myeloid-derived suppressor cell. As reported in the Journal of the National Cancer Institute, Gobbo and colleagues found that the A8 peptide...
PTK2/FAK as Driver of Radioresistance in HPV-Negative Head and Neck Squamous Cell Carcinoma
As reported in Clinical Cancer Research, Skinner and colleagues used proteomic profiling to identify PTK2/FAK as a driver of radioresistance in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma. Using proteomic and transcriptomic analysis of targetable markers, the...
Potential Biomarker for Carfilzomib Activity in CLL
Carfilzomib (Kyprolis) is active in B-cell neoplasms but exhibits heterogeneous activity in chronic lymphocytic leukemia (CLL) samples. As reported in Clinical Cancer Research, Lamothe and colleagues examined the mechanism by which carfilzomib induces CLL cell death. In studies using CLL patient...
APSHO to Hold Skills Workshops for Advanced Practitioners in Oncology
The Advanced Practitioner Society for Hematology and Oncology (APSHPO) has announced a series of workshops to be held in cities nationwide during 2016. APSHO, a nonprofit membership organization consisting of nurse practitioners, physician assistants, pharmacists, clinical nurse specialists, and...
Expect Questions About Potential Trade-Offs of Contralateral Prophylactic Mastectomy
Women who were diagnosed with breast cancer and had contralateral prophylactic mastectomy had only marginal improvement in psychosocial well-being, such as feeling confident and emotionally healthy, according to a study published in the Journal of Clinical Oncology.1 Those who also had breast...
Quality-of-Life Benefits of Contralateral Prophylactic Mastectomy May Be Too Small to Be Clinically Meaningful
Women diagnosed with breast cancer who chose contralateral prophylactic mastectomy reported improvement in psychosocial well-being and breast satisfaction, but “the magnitude of the effect may be too small to be clinically meaningful,” according to a study in the Journal of Clinical Oncology.1...
City of Hope Awarded $2.5 Million Grant to Launch Nutrition Initiative
Funded by a $2.5 million grant from the Conrad N. Hilton Foundation, City of Hope has launched a 5-year initiative to reduce cancer risk in the Los Angeles area by promoting healthy eating and physical activity, particularly among school children. The long-range plan is to replicate the...
Director Selected for NIH’s Precision Medicine Initiative Cohort Program
Francis S. Collins, MD, PhD, Director, National Institutes of Health (NIH), recently released the statement below: I am very pleased to announce the selection of Eric Dishman as Director of the Precision Medicine Initiative (PMI) Cohort Program. Eric will lead NIH’s effort to build the PMI...
